Botanix Pharmaceuticals Ltd (ASX: BOT) Share Price and News
Price
–
Movement
– ( )
(20 mins delayed)
52 Week Range
– - –
1 Year Return
Botanix Pharmaceuticals Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$732.73 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
1.95 billion
Earnings per share
-0.022
Dividend per share
N/A
Year To Date Return
-11.49%
Earnings Yield
N/A
Franking
-
Share Price
–
Day Change
– ( )
52 Week Range
– - –
Yesterday's Close
–
Today's Open
–
Days Range
– - –
Volume
–
Avg. Volume (1 month)
–
Turnover
–
Botanix Pharmaceuticals Ltd (ASX: BOT)
Latest News
Share Gainers
Why the Botanix (ASX:BOT) share price is rocketing 31% higher today
Share Market News
Why the Botanix (ASX:BOT) share price is flying 6%
Share Market News
Why the Botanix (ASX:BOT) share price rocketed 22% to a record high today
Share Market News
Why the Botanix (ASX:BOT) share price is soaring up today
Share Market News
Why the Botanix (ASX:BOT) share price is 15% higher today
Share Market News
The Botanix (ASX:BOT) share price is soaring 15% higher today. Here's why.
Investing
Why I think these small cap ASX shares will perform in 2021
Share Market News
This ASX cannabis share just hit a milestone
Share Market News
What's in store for these 4 ASX cannabis shares in 2020?
Healthcare Shares
How did these ASX cannabis shares perform in 2019?
Share Gainers
Why these ASX cannabis shares are starting the week on a high
Share Market News
Which ASX cannabis shares should you buy in November?
BOT ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|
About Botanix Pharmaceuticals Ltd
Botanix Pharmaceuticals Ltd is a dermatology company. The company focuses on developing safe and effective topical treatments for serious skin conditions. It has an exclusive license to use a proprietary drug delivery system in all skin diseases. The company's product pipeline includes BTX1503 - Moderate to Severe Acne, BTX1204 - Atopic Dermatitis, and BTX 1702 - Rosacea, Sofdra - Axillary Hyperhidrosis, and others. The majority of Revenue is Derived from Australia.
BOT Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 19 May 2025 | $0.38 | $-0.01 | -2.60% | 6,913,264 | $0.39 | $0.39 | $0.37 |
| 16 May 2025 | $0.39 | $0.01 | 2.63% | 6,167,950 | $0.39 | $0.40 | $0.38 |
| 15 May 2025 | $0.38 | $-0.02 | -5.00% | 4,876,364 | $0.40 | $0.41 | $0.38 |
| 14 May 2025 | $0.40 | $0.01 | 2.53% | 8,684,965 | $0.40 | $0.41 | $0.39 |
| 13 May 2025 | $0.40 | $-0.01 | -2.47% | 17,962,682 | $0.42 | $0.44 | $0.40 |
| 12 May 2025 | $0.41 | $-0.06 | -12.90% | 39,150,601 | $0.44 | $0.44 | $0.38 |
| 09 May 2025 | $0.47 | $0.00 | 0.00% | 2,843,339 | $0.47 | $0.47 | $0.45 |
| 08 May 2025 | $0.47 | $0.02 | 4.44% | 5,793,863 | $0.45 | $0.47 | $0.45 |
| 07 May 2025 | $0.45 | $0.01 | 2.27% | 6,802,864 | $0.45 | $0.45 | $0.42 |
| 06 May 2025 | $0.44 | $-0.01 | -2.22% | 3,382,107 | $0.45 | $0.46 | $0.44 |
| 05 May 2025 | $0.45 | $-0.01 | -2.20% | 4,320,015 | $0.46 | $0.48 | $0.45 |
| 02 May 2025 | $0.46 | $0.01 | 2.25% | 10,253,453 | $0.45 | $0.47 | $0.44 |
| 01 May 2025 | $0.45 | $-0.01 | -2.22% | 9,919,533 | $0.46 | $0.46 | $0.42 |
| 30 Apr 2025 | $0.45 | $0.01 | 2.27% | 10,890,639 | $0.45 | $0.46 | $0.43 |
| 29 Apr 2025 | $0.44 | $0.04 | 9.88% | 7,963,814 | $0.41 | $0.45 | $0.41 |
| 28 Apr 2025 | $0.41 | $-0.02 | -4.76% | 5,983,154 | $0.43 | $0.44 | $0.41 |
| 24 Apr 2025 | $0.42 | $-0.01 | -2.35% | 10,701,984 | $0.42 | $0.44 | $0.40 |
| 23 Apr 2025 | $0.43 | $0.03 | 7.59% | 6,938,022 | $0.41 | $0.43 | $0.41 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 20 Mar 2025 | Daniel Sharp | Exercise | 4,000,000 | $1,740,000 |
Exercise of options.
|
| 20 Mar 2025 | Daniel Sharp | Issued | 3,111,145 | $1,353,348 |
Exercise of options.
|
| 27 Feb 2025 | Stewart Washer | Issued | 3,990,099 | $1,815,495 |
Exercise of options.
|
| 27 Feb 2025 | Stewart Washer | Exercise | 5,000,000 | $2,275,000 |
Exercise of options.
|
| 15 Jan 2025 | Vince Ippolito | Sell | 3,800,000 | $1,672,000 |
On-market trade.
|
| 08 Jan 2025 | Vince Ippolito | Buy | 8,000,000 | $3,680,000 |
Conversion of securities.
|
| 08 Jan 2025 | Vince Ippolito | Exercise | 8,000,000 | $3,680,000 |
Conversion of securities. 16,000,000 - Performance Rights
|
| 07 Jan 2025 | Vince Ippolito | Transfer | 10,801,644 | $4,158,632 |
Off-market transfer. 10,801,644 Fully Paid Ordinary Shares were moved off
market |
| 07 Jan 2025 | Vince Ippolito | Transfer | 10,801,644 | $4,158,632 |
Off-market transfer. 10,801,644 Fully Paid Ordinary Shares were moved off
market |
| 02 Dec 2024 | Matthew (Matt) Callahan | Issued | 3,000,000 | $1,050,000 |
Issue of securities. 3,000,000 Performance Right
|
| 02 Dec 2024 | Stewart Washer | Issued | 3,000,000 | $1,050,000 |
Issue of securities. 3,333,333 Rights
|
| 02 Dec 2024 | H. William Bosch | Issued | 3,000,000 | $1,050,000 |
Issue of securities. 3,000,000 Performance Rights
|
| 02 Dec 2024 | Vince Ippolito | Issued | 24,000,000 | $8,400,000 |
Issue of securities. 24,000,000 Performance Rights
|
| 02 Dec 2024 | Daniel Sharp | Issued | 3,000,000 | $1,050,000 |
Issue of securities. 3,333,333 Rights
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Matthew (Matt) Callahan | Executive Director | Feb 2020 |
Mr Callahan is a life sciences executive based in Philadelphia and a founder of Botanix. He has been the founding CEO or Executive Director of a number of ASX listed and private pharmaceutical and health tech companies, including iCeutica Inc, Churchill Pharmaceuticals LLC, Dimerix Biosciences Ltd, Orthocell Ltd, Respirion Pharmaceuticals Pty Ltd, Rumin8 Pty Ltd and Emyria Ltd. Mr Callahan has led the development and commercialization of several products that have received FDA and other global regulatory approvals, he has more than 25 years of industry, IP and legal experience.
|
| Dr Stewart James Washer | Non-Executive Director | Feb 2019 |
Dr Washer has CEO and board experience in medical biotech and device companies. Dr Washer chaired Hatchtech Pty Ltd that was sold in 2015 for A$279m and was a director of iCeutica that was sold to US private equity investors in 2010. He has been a Senator with Murdoch University and a director of AusBiotech Ltd.
|
| Dr H. William Bosch | Non-Executive Director | Jul 2023 |
Dr Bosch is a pharmaceutical executive with more than 30 years of experience and industry leadership in pharmaceutical R&D. Dr. Bosch served as CSO of iCeutica where he was the principal architect of SoluMatrix drug delivery technology, used in four FDA-approved prescription drug products. Earlier in his career Dr Bosch was a creator in the application of nanotechnology to pharmaceutical product development. He served as a co-founder of NanoSystems LLC in 1995 and co-inventor of NanoCrystal Technology, leading to the development and FDA approval of seven prescription drug products for a variety of indications and routes of administration.
|
| Mr Vince Ippolito | PresidentExecutive ChairmanExecutive Director | May 2019 |
Mr Ippolito has more than 35 years of experience in the pharmaceuticals industry, including over 20 years of experience in dermatology. He most recently served as President and Chief Operating Officer of Dermavant Sciences, a specialty biopharmaceutical company that is commercialising products which treat inflammatory skin diseases and medical dermatologic conditions. Prior to his role at Dermavant Sciences, Mr Ippolito served as the Chief Commercial Officer and Executive Vice President of Anacor Pharmaceuticals, a dermatology-based biopharmaceutical company.
|
| Mr Daniel Sharp | Non-Executive Director | Mar 2022 |
Mr Sharp is an investment banker with more than 30 years of experience in capital markets globally, advising the boards of technology and healthcare-based organisations. He also has experience in sourcing and servicing both of institutional and private wealth investors globally. Mr Sharp was a Corporate Finance Executive Director of Canaccord Genuity for 8 years and previously spearheaded the Corporate Finance departments at both Shaw and Partners and Lodge Partners.
|
| Ms Susan Patricia Park | Company Secretary | Apr 2023 |
-
|
| Dr Howie McKibbon | Chief Executive Officer | Aug 2023 |
-
|
| Howie McKibbon | Chief Executive Officer |
-
|
|
| Graeme Morissey | Chief Financial Officer |
-
|
|
| Susan Patricia Park | Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Citicorp Nominees Pty Limited | 158,445,435 | 8.73% |
| National Nominees Limited | 111,876,013 | 6.17% |
| J P Morgan Nominees Australia Pty Limited | 99,001,452 | 5.46% |
| Shenasaby Investments Pty Ltd <The Shenasaby A/C> | 73,420,124 | 4.05% |
| UBS Nominees Pty Ltd | 53,608,927 | 2.96% |
| Caperi Pty Ltd <Caperi A/C> | 52,573,784 | 2.90% |
| Hsbc Custody Nominees (Australia) Limited | 47,689,862 | 2.63% |
| BNP Paribas Nominees Pty Ltd <Agency Lending A/C> | 34,339,755 | 1.89% |
| BNP Paribas Nominees Pty Ltd<Ib Au Noms Retailclient> | 25,783,783 | 1.42% |
| Zenith Pacific Limited | 22,272,222 | 1.23% |
| Warbont Nominees Pty Ltd <Unpaid Entrepot A/C> | 20,067,318 | 1.11% |
| Dr Henry William Bosch | 18,836,702 | 1.04% |
| Yarraandoo Pty Ltd <Yarraandoo Super Fund A/C> | 15,166,667 | 0.84% |
| Moffatt Investments Pty Ltd <Matthew Moffatt Family A/C> | 12,378,182 | 0.68% |
| Rollo Corp Property Holdings Pty Ltd <Rollo Corp Property A/C> | 10,930,000 | 0.60% |
| Mr Vincent Peter Ippolito | 10,801,644 | 0.60% |
| BNP Paribas Noms Pty Ltd | 9,542,034 | 0.53% |
| UBS Nominees Pty Ltd i | 9,523,810 | 0.53% |
| Netwealth Investments Limited <Wrap Services A/C> | 8,277,790 | 0.46% |
| Mr Nicolas Stephane Fayd'Herbe <Fayd'Herbe Family A/C> | 7,888,032 | 0.43% |